COLL Stock Recent News

COLL LATEST HEADLINES

COLL Stock News Image - seekingalpha.com

Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Colleen Tupper - Executive VP & CFO Ian Karp - Corporate Participant Scott Dreyer - Executive VP & Chief Commercial Officer Vikram Karnani - CEO, President, Executive VP & Director Conference Call Participants David A. Amsellem - Piper Sandler & Co., Research Division John Todaro - Needham & Company, LLC, Research Division Leszek Sulewski - Truist Securities, Inc., Research Division Operator Greetings, and welcome to the Collegium Pharmaceuticals Second Quarter 2025 Earnings Conference Call.

seekingalpha.com 2025 Aug 07
COLL Stock News Image - fool.com

Collegium (COLL) Q2 Revenue Jumps 29%

fool.com 2025 Aug 07
COLL Stock News Image - zacks.com

Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

zacks.com 2025 Aug 07
COLL Stock News Image - zacks.com

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.68 per share, beating the Zacks Consensus Estimate of $1.62 per share. This compares to earnings of $1.62 per share a year ago.

zacks.com 2025 Aug 07
COLL Stock News Image - globenewswire.com

– Generated Record Quarterly Net Revenue of $188.0 Million, Up 29% Year-over-Year – – Generated Record Quarterly Jornay PM ® Net Revenue of $32.6 Million and Grew Prescriptions by 23% Year-over-Year – – Generated Net Revenue of $155.4 Million from the Pain Portfolio, Up 7% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Raised Full-Year 2025 Net Revenue Guidance to be in the Range of $745 to $760 Million and Adjusted EBITDA Guidance in the Range of $440 to $455 Million – – Ended Q2'25 with Cash, Cash Equivalents and Marketable Securities of $222.2 Million – – Board of Directors Authorized $150 Million Share Repurchase Program – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON, Mass.

globenewswire.com 2025 Aug 07
COLL Stock News Image - zacks.com

The consensus price target hints at a 33.9% upside potential for Collegium Pharmaceutical (COLL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

zacks.com 2025 Jul 25
COLL Stock News Image - zacks.com

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

zacks.com 2025 Jul 25
COLL Stock News Image - globenewswire.com

STOUGHTON, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report second quarter 2025 financial results before the market opens on Thursday, August 7, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET.

globenewswire.com 2025 Jul 24
COLL Stock News Image - marketbeat.com

Stock buybacks remain one of the most effective tools for boosting share prices, especially when backed by solid fundamentals. When a company is healthy, repurchasing shares reduces the float, enhances earnings per share, and signals confidence to the market.

marketbeat.com 2025 Jul 10
COLL Stock News Image - globenewswire.com

STOUGHTON, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced its Board of Directors has authorized a new share repurchase program to repurchase up to $150 million in common stock through December 31, 2026.

globenewswire.com 2025 Jul 07
10 of 50